Zoetis Inc. Class A Common Stock (ZTS): M&A News

ZTS – Abaxis to be acquired by Zoetis for $83 per share in cash, or approximately $2.0 billion.


Key Facts Surrounding This News Item


  • ZTS had a POWR Rating of A (Strong Buy) coming into today.
  • ZTS was 0.84% above its 10-Day Moving Average coming into today.
  • ZTS was -0.62% below its 20-Day Moving Average coming into today.
  • ZTS was -0.26% below its 50-Day Moving Average coming into today.
  • ZTS was 4.19% above its 100-Day Moving Average coming into today.
  • ZTS was 14.36% above its 200-Day Moving Average coming into today.
  • ZTS had returned +15.60% year-to-date leading up to today’s news, versus a +2.00% return from the benchmark S&P 500 during the same period.

More Info About Zoetis Inc. Class A Common Stock (ZTS)


Zoetis Inc. discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. The company was founded in 1952 and is based in Florham Park, New Jersey. View our full ZTS ticker page with ratings, news, and more.

Try StockNews.com Premium Today!


Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!

Sign Up Now

ZTS at a Glance

ZTS Current POWR Rating™
Overall POWR Rating™
ZTS Current Price $91.26 0.48%
More ZTS Ratings, Data, and News

ZTS Price Reaction

The day of this event (May. 16, 2018)
ZTS Closing Price$82.73 0.20%
ZTS Volume3,225,929
29.62% from avg
Leading up to this event
ZTS 1-mo return1.49%
After this event
ZTS 1-day return0.08%
ZTS 3-day return2.76%
ZTS 5-day return2.19%

ZTS Price Chart



More Zoetis Inc. Class A Common Stock (ZTS) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ZTS News
Page generated in 1.441 seconds.